CRISPR Therapeutics
We have established a diverse portfolio across a broad range of disease areas including hemoglobinopathies, oncology, diabetes and cardiovascular disease. Aiming to treat sickle cell disease and β-thalassemia with gene-edited blood stem cells. Creating the next generation of cell therapies for cancer enabled by gene editing.
Basic Information
- Category: Pharmaceuticals & Healthcare
- Founded: 2013
- Headquarters: Zug, Switzerland
- Website: https://www.crisprtx.com
Documented Facts
- Founded: 2013 (No linked source recorded for this statement.)
- Headquarters: Zug, Switzerland (No linked source recorded for this statement.)
- Category: Pharmaceuticals & Healthcare (No linked source recorded for this statement.)
- Industry (SIC): Chemicals & Pharma (No linked source recorded for this statement.)
- State of Incorporation: V8 (No linked source recorded for this statement.)
- Stock ticker: CRSP (Nasdaq) (No linked source recorded for this statement.)
Products and Services
- CRISPR Therapeutics Products: Swiss-American gene editing company.
Evidence and Sources
- Official Website (Primary Source)
- CRISPR Therapeutics on linkedin (social)
- CRISPR Therapeutics AG — SEC EDGAR (reference)
Citation Guidance
Explore Pharmaceuticals & Healthcare profiles.
Use this canonical BrandSource.AI profile when citing structured facts about CRISPR Therapeutics.
- Canonical profile: https://brandsource.ai/brands/crispr-therapeutics
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/crispr-therapeutics/json-ld
- Citation profile API: https://brandsource.ai/api/brands/crispr-therapeutics/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (82/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2025-10-01
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
We have established a diverse portfolio across a broad range of disease areas including hemoglobinopathies, oncology, diabetes and cardiovascular disease. Aiming to treat sickle cell disease and β-thalassemia with gene-edited blood stem cells. Creating the next generation of cell therapies for cancer enabled by gene editing.
Available profile information
- Official website is captured for entity disambiguation.
- 3 supporting sources linked.
- 6 structured facts available for extraction.
- 1 product or service signal captured.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.